Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBanco Santander, S.A.
Latest Disclosed Ownership99,388 shares
Latest Disclosed Value $ 44,380,718
Banco Santander, S.A. reports 1.39% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 8, 2026 - Banco Santander, S.A. filed a 13F-HR form disclosing ownership of 99,388 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $44,380,718 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 98,027 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 1.39% during the quarter. The current value of the position is $42,571,856 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 99,388 1,361 1.39 44,381 -0.14 0.2097
2026-02-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 98,027 18,621 23.45 44,442 42.91 0.3328
2025-11-12 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 79,406 9,218 13.13 31,099 -0.48 0.2761
2025-08-01 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 70,188 6,160 9.62 31,248 0.66 0.2967
2025-05-09 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 64,028 15,844 32.88 31,042 59.99 0.3426
2025-02-07 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 48,184 32,316 203.66 19,404 162.95 0.2334
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,868 -560 -3.41 7,380 -4.17 0.0870
2024-07-29 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,428 -525 -3.10 7,700 8.66 0.0954
2024-05-10 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,953 -3,442 -16.88 7,087 -14.61 0.0854
2024-02-09 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 20,395 -2,160 -9.58 8,299 5.80 0.0981
2023-11-08 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 22,555 -1,370 -5.73 7,843 -6.84 0.1112
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,925 -5,530 -18.77 8,419 -9.28 0.1104
2023-05-10 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,455 -7,880 -21.11 9,280 -13.92 0.1389
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 37,335 -4,135 -9.97 10,782 -10.22 0.1619
2022-11-08 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 41,470 -1,150 -2.70 12,008 -0.02 0.1602
2022-07-28 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 42,620 -12,572 -22.78 12,010 -16.61 0.1600
2022-05-09 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 55,192 7,930 16.78 14,403 38.77 0.1546
2022-02-09 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 47,262 1,300 2.83 10,379 24.49 0.0559
2021-11-08 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 45,962 43,030 1,467.60 8,337 1,310.66 0.0448
2021-07-29 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,932 -1,324 -31.11 591 -35.34 0.0033
2021-05-10 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,256 357 9.16 914 -0.76 0.0064
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,899 -14,622 -78.95 921 -81.73 0.0066
2020-11-09 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,521 -107,431 -85.30 5,040 -86.22 0.0663
2020-08-05 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 125,952 -48,443 -27.78 36,565 -11.89 0.4743
2020-05-11 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 174,395 74,906 75.29 41,497 90.50 0.4751
2020-02-07 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 99,489 75,993 323.43 21,783 447.17 0.2012
2019-11-06 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,496 -95,083 -80.19 3,981 -81.69 0.0387
2019-08-07 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 118,579 -235,594 -66.52 21,745 -66.62 0.2206
2019-05-13 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 354,173 -898 -0.25 65,150 10.73 0.7355
2019-02-12 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 355,071 -107 -0.03 58,838 -14.05 0.7435
2018-11-13 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 355,178 1,924 0.54 68,457 14.02 0.7812
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 353,254 13,799 4.07 60,039 8.52 0.6994
2018-05-14 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 339,455 2,655 0.79 55,325 9.61 0.6471
2018-02-14 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 336,800 9,800 3.00 50,473 1.52 0.7229
2017-11-13 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 327,000 327,000 49,717 0.8198
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.